TAP2

Antigen peptide transporter 2 · Q03519 · TAP2 on Sugi Atlas →

0 patent compounds predicted against TAP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TAP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
TEIPP Immunotherapy in Patients With NSCLC PHASE1/PHASE2COMPLETED
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma PHASE2COMPLETED
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood PHASE1/PHASE2COMPLETED
Ovarian Dendritic Cell Vaccine Trial PHASE2UNKNOWN
Consolidation Therapy in Patients With Hematologic Malignancies PHASE1/PHASE2WITHDRAWN
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection PHASE1/PHASE2COMPLETED
A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies PHASE1/PHASE2COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence PHASE2COMPLETED
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma PHASE2COMPLETED
Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer PHASE2UNKNOWN
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation PHASE1/PHASE2COMPLETED
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes PHASE2COMPLETED
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma PHASE2COMPLETED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive PHASE1/PHASE2COMPLETED
Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients PHASE1UNKNOWN
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma PHASE1RECRUITING
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) PHASE1UNKNOWN
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma PHASE1COMPLETED
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer PHASE1COMPLETED
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies PHASE1UNKNOWN
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer PHASE1COMPLETED
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery PHASE1COMPLETED
Dose Escalation Study of Immunomodulatory Nanoparticles PHASE1ACTIVE_NOT_RECRUITING
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma PHASE1COMPLETED
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors EARLY_PHASE1UNKNOWN
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer EARLY_PHASE1RECRUITING
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma EARLY_PHASE1COMPLETED
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers nanRECRUITING
Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TAP2 binder may also engage these)

ProteinNameSimilarity
P36372 0.996 P36372 →
TAP1 Antigen peptide transporter 1 0.992 landscape →
Q28433 0.991 Q28433 →
P36371 0.989 P36371 →
P36370 0.987 P36370 →
P21958 0.982 P21958 →
Q5T3U5 0.982 Q5T3U5 →
Q5RFQ9 0.979 Q5RFQ9 →
Q9NUT2 0.974 Q9NUT2 →
Q8R4P9 0.973 Q8R4P9 →
Q9NRK6 0.973 Q9NRK6 →
O88269 0.973 O88269 →
O95255 0.972 O95255 →
Q9R1S7 0.972 Q9R1S7 →
Q643R3 0.970 Q643R3 →
Q9NP78 0.969 Q9NP78 →
Q9JJ59 0.969 Q9JJ59 →
O70595 0.969 O70595 →
Q9CTG6 0.968 Q9CTG6 →
Q9CXJ4 0.967 Q9CXJ4 →
ABCC3 ATP-binding cassette sub-family C member 3 0.967 landscape →
B2RX12 0.965 B2RX12 →
Q7TNJ2 0.964 Q7TNJ2 →
Q9QYJ4 0.964 Q9QYJ4 →
Q91V24 0.964 Q91V24 →
Q91W34 0.964 Q91W34 →
B2GUP8 0.963 B2GUP8 →
Q5RKI8 0.962 Q5RKI8 →
O88563 0.962 O88563 →
P51839 0.962 P51839 →